R. 1. Crohn, B. Ginzburg, L. Oppenheimer, and G. , Regional ileitis. A pathological and clinical entity, By Burril B. Crohn, vol.251, issue.1, pp.73-79, 1932.

F. Baert, M. Noman, S. Vermeire, G. Van-assche, G. Dh et al., Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease, New England Journal of Medicine, vol.348, issue.7, pp.348601-608, 2003.
DOI : 10.1056/NEJMoa020888

G. Vernier-massouille, M. Balde, J. Salleron, D. Turck, J. Dupas et al., Natural History of Pediatric Crohn's Disease: A Population-Based Cohort Study, Gastroenterology, vol.135, issue.4, pp.1106-1113, 2008.
DOI : 10.1053/j.gastro.2008.06.079

B. Yan, R. Panaccione, and L. Sutherland, I am Jewish, Inflammatory Bowel Diseases, vol.72, issue.Supplement, pp.26-27, 2008.
DOI : 10.1086/367848

V. Nerich, E. Monnet, E. A. Louafi, S. Ramee, C. Rican et al., Geographical variations of inflammatory bowel disease in France: A study based on national health insurance data, Inflammatory Bowel Diseases, vol.12, issue.3, pp.218-226, 2006.
DOI : 10.1053/gast.2003.50021

URL : https://hal.archives-ouvertes.fr/hal-00466309

V. Chouraki, G. Savoye, L. Dauchet, G. Vernier-massouille, J. Dupas et al., The changing pattern of Crohn's disease incidence in northern France: a continuing increase in the 10-to 19-year-old age bracket, Aliment Pharmacol Ther, issue.10, pp.331133-1142, 1988.

E. Benchimol, A. Guttmann, A. Griffiths, L. Rabeneck, D. Mack et al., Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data, Gut, vol.58, issue.11, pp.581490-1497, 2009.
DOI : 10.1136/gut.2009.188383

F. Carbonnel, G. Macaigne, L. Beaugerie, J. Gendre, and J. Cosnes, Crohn's disease severity in familial and sporadic cases, Gut, vol.44, issue.1, pp.91-95, 1999.
DOI : 10.1136/gut.44.1.91

R. Russell and J. Satsangi, IBD: a family affair, Best Practice & Research Clinical Gastroenterology, vol.18, issue.3, pp.525-539, 2004.
DOI : 10.1016/j.bpg.2003.12.006

L. Halme, P. Paavola-sakki, U. Turunen, M. Lappalainen, M. Farkkila et al., Family and twin studies in inflammatory bowel disease. World journal of gastroenterology : WJG, pp.3668-3672, 2006.

S. Naser, M. Arce, A. Khaja, M. Fernandez, N. Naser et al., Role of ATG16L, NOD2 and IL23R in Crohn's disease pathogenesis, World journal of gastroenterology : WJG, vol.2012, issue.185, pp.412-424

J. Van-limbergen, R. Russell, E. Nimmo, and J. Satsangi, The Genetics of Inflammatory Bowel Disease, The American Journal of Gastroenterology, vol.11, issue.12, pp.2820-2831, 2007.
DOI : 10.1111/j.1365-2036.2005.02635.x

S. Kugathasan, R. Baldassano, J. Bradfield, P. Sleiman, M. Imielinski et al., Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease, Nature Genetics, vol.164, issue.10, pp.401211-1215, 2008.
DOI : 10.1038/nature06010

URL : http://europepmc.org/articles/pmc2770437?pdf=render

M. Lacher, J. Helmbrecht, S. Schroepf, S. Koletzko, A. Ballauff et al., NOD2 mutations predict the risk for surgery in pediatric-onset Crohn's disease, Journal of Pediatric Surgery, vol.45, issue.8, pp.451591-1597, 2010.
DOI : 10.1016/j.jpedsurg.2009.10.046

D. Gaya, R. Russell, E. Nimmo, and J. Satsangi, New genes in inflammatory bowel disease: lessons for complex diseases?, The Lancet, vol.367, issue.9518, pp.1271-1284, 2006.
DOI : 10.1016/S0140-6736(06)68345-1

J. Cosnes, Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice, Best Practice & Research Clinical Gastroenterology, vol.18, issue.3, pp.481-496, 2004.
DOI : 10.1016/j.bpg.2003.12.003

S. Mahid, K. Minor, A. Stromberg, and S. Galandiuk, Active and Passive Smoking in Childhood Is Related to the Development of Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.13, issue.4, pp.431-438, 2007.
DOI : 10.1093/ije/13.2.235

D. Amre, D. Souza, S. Morgan, K. Seidman, G. Lambrette et al., Imbalances in Dietary Consumption of Fatty Acids, Vegetables, and Fruits Are Associated With Risk for Crohn's Disease in Children, The American Journal of Gastroenterology, vol.12, issue.170, pp.2016-2025, 2007.
DOI : 10.1136/gut.2004.054353

P. Jantchou, E. Monnet, and F. Carbonnel, [Environmental risk factors in Crohn's disease and ulcerative colitis (excluding tobacco and appendicectomy)], Gastroenterol Clin Biol, vol.30, pp.6-7859, 2006.

P. Eckburg, E. Bik, C. Bernstein, E. Purdom, L. Dethlefsen et al., Diversity of the Human Intestinal Microbial Flora, Science, vol.308, issue.5728, pp.1635-1638, 2005.
DOI : 10.1126/science.1110591

A. Schwiertz, M. Jacobi, J. Frick, M. Richter, K. Rusch et al., Microbiota in Pediatric Inflammatory Bowel Disease, The Journal of Pediatrics, vol.157, issue.2, pp.240-244, 2010.
DOI : 10.1016/j.jpeds.2010.02.046

H. Sokol, P. Seksik, J. Furet, O. Firmesse, I. Nion-larmurier et al., Low counts of Faecalibacterium prausnitzii in colitis microbiota, Inflammatory Bowel Diseases, vol.40, issue.8, pp.1183-1189, 2009.
DOI : 10.1128/JCM.40.12.4423-4427.2002

URL : https://hal.archives-ouvertes.fr/hal-00657435

A. Sawczenko and B. Sandhu, Presenting features of inflammatory bowel disease in Great Britain and Ireland, Archives of Disease in Childhood, vol.88, issue.11, pp.995-1000, 2003.
DOI : 10.1136/adc.88.11.995

F. Vasseur, C. Gower-rousseau, G. Vernier-massouille, J. Dupas, V. Merle et al., Nutritional Status and Growth in Pediatric Crohn's Disease: A Population-Based Study, The American Journal of Gastroenterology, vol.105, issue.8, pp.1051893-1900, 2010.
DOI : 10.1002/ibd.20069

A. Levine, A. Griffiths, J. Markowitz, D. Wilson, D. Turner et al., Pediatric modification of the Montreal classification for inflammatory bowel disease, Inflammatory Bowel Diseases, vol.31, issue.6suppl, pp.1314-1321, 2011.
DOI : 10.1016/S1054-139X(02)00485-8

C. Solem, E. Loftus, J. Tremaine, W. Harmsen, W. Zinsmeister et al., Correlation of C-Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.128, issue.8, pp.11707-712, 2005.
DOI : 10.1097/01.CRD.0000077906.74217.6E

E. Mainardi, V. Villanacci, G. Bassotti, B. Liserre, E. Rossi et al., Diagnostic value of serological assays in pediatric inflammatory bowel disorders. Digestion Oussalah A, Gueant JL, Peyrin-Biroulet L: Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases, Aliment Pharmacol Ther, vol.75, issue.2910, pp.210-214, 2007.

R. Canani, G. Terrin, L. Rapacciuolo, E. Miele, M. Siani et al., Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, pp.40547-553, 2008.

J. Mary and R. Modigliani, Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study, Gut, issue.7, pp.30983-989, 1989.

D. Nardo, G. Oliva, S. Ferrari, F. Riccioni, M. Staiano et al., Usefulness of wireless capsule endoscopy in paediatric inflammatory bowel disease. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, pp.43220-224, 2011.

A. Lucendo and D. Guagnozzi, Small bowel video capsule endoscopy in Crohn's disease: What have we learned in the last ten years? World journal of gastrointestinal endoscopy, pp.23-29, 2011.

B. Pigneur, P. Seksik, S. Viola, J. Viala, L. Beaugerie et al., Natural history of Crohn??s disease, Inflammatory Bowel Diseases, vol.34, issue.6, pp.953-961, 2010.
DOI : 10.1136/gut.34.7.939

R. Harvey and J. Bradshaw, A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY, The Lancet, vol.315, issue.8167, p.514, 1980.
DOI : 10.1016/S0140-6736(80)92767-1

J. Hyams, G. Ferry, F. Mandel, J. Gryboski, P. Kibort et al., Development and validation of a pediatric Crohn's disease activity index, J Pediatr Gastroenterol Nutr, vol.12, issue.4, pp.439-447, 1991.

N. Gupta, A. Bostrom, B. Kirschner, G. Ferry, B. Gold et al., Incidence of stricturing and penetrating complications of Crohn??s disease diagnosed in pediatric patients, Inflammatory Bowel Diseases, vol.97, issue.4, pp.638-644, 2010.
DOI : 10.1111/j.1572-0241.2002.05915.x

K. Thia, W. Sandborn, W. Harmsen, A. Zinsmeister, E. Loftus et al., Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort, Gastroenterology, vol.139, issue.4, pp.1147-1155, 2010.
DOI : 10.1053/j.gastro.2010.06.070

B. Begue, J. Verdier, F. Rieux-laucat, O. Goulet, A. Morali et al., Defective IL10 Signaling Defining a Subgroup of Patients With Inflammatory Bowel Disease, The American Journal of Gastroenterology, vol.29, issue.8, pp.1544-1555, 2011.
DOI : 10.1016/j.immuni.2008.11.003

E. Glocker, D. Kotlarz, K. Boztug, E. Gertz, A. Schaffer et al., Inflammatory Bowel Disease and Mutations Affecting the Interleukin-10 Receptor, New England Journal of Medicine, vol.361, issue.21, pp.3612033-2045, 2009.
DOI : 10.1056/NEJMoa0907206

M. Kim, J. Lee, J. Lee, J. Kim, and Y. Choe, Infliximab therapy in children with Crohn???s disease: a one-year evaluation of efficacy comparing ???top-down??? and ???step-up??? strategies, Acta Paediatrica, vol.48, issue.Suppl 2
DOI : 10.1080/10428190701345433

P. Dziechciarz, A. Horvath, R. Shamir, and H. Szajewska, Meta-analysis: enteral nutrition in active Crohn???s disease in children, Alimentary Pharmacology & Therapeutics, vol.24, issue.Suppl. 1, pp.795-806, 2007.
DOI : 10.1016/0016-5085(88)90230-2

M. Zachos, M. Tondeur, and A. Griffiths, Enteral nutritional therapy for induction of remission in Crohn's disease, Cochrane Database Syst Rev, vol.2007, issue.1, p.542

T. Yamamoto, M. Nakahigashi, and A. Saniabadi, Review article: diet and inflammatory bowel disease - epidemiology and treatment, Alimentary Pharmacology & Therapeutics, vol.126, issue.Suppl. 10, pp.99-112, 2009.
DOI : 10.1080/00365520510023729

J. Cezard, A. Munck, O. Mouterde, A. Morali, C. Lenaerts et al., Prevention of relapse by mesalazine (Pentasa??) in pediatric Crohn's disease: A multicenter, double-blind, randomized, placebo-controlled trial, Gastroent??rologie Clinique et Biologique, vol.33, issue.1, pp.31-40, 2009.
DOI : 10.1016/j.gcb.2008.07.007

J. Escher, Budesonide versus prednisolone for the treatment of active Crohn's disease in children, European Journal of Gastroenterology & Hepatology, vol.16, issue.1, pp.47-54, 2004.
DOI : 10.1097/00042737-200401000-00008

L. Riello, C. Talbotec, H. Garnier-lengline, B. Pigneur, J. Svahn et al., Tolerance and efficacy of azathioprine in pediatric Crohn's disease, Inflamm Bowel Dis, issue.10, pp.172138-2143, 2011.

L. Armstrong, J. Sharif, P. Galloway, P. Mcgrogan, J. Bishop et al., Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine, Alimentary Pharmacology & Therapeutics, vol.374, issue.Suppl. 1, pp.1106-1114, 2011.
DOI : 10.1016/S0140-6736(09)61302-7

M. Osterman, R. Kundu, G. Lichtenstein, and J. Lewis, Association of 6-Thioguanine Nucleotide Levels and Inflammatory Bowel Disease Activity: A Meta-Analysis, Gastroenterology, vol.130, issue.4, pp.1047-1053, 2006.
DOI : 10.1053/j.gastro.2006.01.046

D. Turner, A. Grossman, J. Rosh, S. Kugathasan, A. Gilman et al., Methotrexate Following Unsuccessful Thiopurine Therapy in Pediatric Crohn's Disease, The American Journal of Gastroenterology, vol.17, issue.2, pp.2804-2812, 2007.
DOI : 10.1136/gut.48.5.591

L. Felipez, R. Gokhale, M. Tierney, and B. Kirschner, Thalidomide Use and Outcomes in Pediatric Patients With Crohn Disease Refractory to Infliximab and Adalimumab, Journal of Pediatric Gastroenterology and Nutrition, vol.54, issue.1, pp.28-33
DOI : 10.1097/MPG.0b013e318228349e

J. Rosh, T. Lerer, J. Markowitz, S. Goli, P. Mamula et al., Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohn???s Disease, The American Journal of Gastroenterology, vol.132, issue.12, pp.3042-3049, 2009.
DOI : 10.1097/MPG.0b013e3181957a11

S. Schreiber, M. Khaliq-kareemi, I. Lawrance, O. Thomsen, S. Hanauer et al., Maintenance Therapy with Certolizumab Pegol for Crohn's Disease, New England Journal of Medicine, vol.357, issue.3, pp.239-250, 2007.
DOI : 10.1056/NEJMoa062897

J. Hyams, D. Wilson, A. Thomas, R. Heuschkel, S. Mitton et al., Natalizumab Therapy for Moderate to Severe Crohn Disease in Adolescents, Journal of Pediatric Gastroenterology and Nutrition, vol.44, issue.2, pp.185-191, 2007.
DOI : 10.1097/01.mpg.0000252191.05170.e7

B. Bressler and B. Sands, Review article: medical therapy for fistulizing Crohn's disease, Alimentary Pharmacology and Therapeutics, vol.17, issue.48
DOI : 10.1111/j.1572-0241.1999.00848.x

S. Danese, New therapies for inflammatory bowel disease: from the bench to the bedside, Gut, vol.61, issue.6, pp.918-932
DOI : 10.1136/gutjnl-2011-300904

U. Klotz, A. Teml, and M. Schwab, Clinical Pharmacokinetics and Use??of??Infliximab, Clinical Pharmacokinetics, vol.20, issue.1, pp.645-660, 2007.
DOI : 10.3748/wjg.v11.i8.1187

A. Fasanmade, O. Adedokun, M. Blank, H. Zhou, and H. Davis, Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials, Clinical Therapeutics, vol.33, issue.7, pp.33946-964, 2011.
DOI : 10.1016/j.clinthera.2011.06.002

T. Horiuchi, H. Mitoma, S. Harashima, H. Tsukamoto, and T. Shimoda, Transmembrane TNFalpha: structure, function and interaction with anti-TNF agents, Rheumatology (Oxford), vol.2010, issue.497, pp.1215-1228
DOI : 10.1093/rheumatology/keq031

URL : https://academic.oup.com/rheumatology/article-pdf/49/7/1215/5049610/keq031.pdf

G. Veres, R. Baldassano, and P. Mamula, Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease, Drugs, vol.40, issue.12, pp.1703-1723, 2007.
DOI : 10.1053/gast.2003.50182

W. Crandall, J. Hyams, S. Kugathasan, A. Griffiths, J. Zrubek et al., Infliximab Therapy in Children With Concurrent Perianal Crohn Disease: Observations From REACH, Journal of Pediatric Gastroenterology and Nutrition, vol.49, issue.2
DOI : 10.1097/MPG.0b013e3181a70f21

L. Peyrin-biroulet, P. Deltenre, N. De-suray, J. Branche, W. Sandborn et al., Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials, Clinical Gastroenterology and Hepatology, vol.6, issue.6, pp.644-653, 2008.
DOI : 10.1016/j.cgh.2008.03.014

D. Jacobstein, J. Markowitz, B. Kirschner, G. Ferry, S. Cohen et al., Premedication and Infusion Reactions With Infliximab: Results From a Pediatric Inflammatory Bowel Disease Consortium, Inflammatory Bowel Diseases, vol.33, issue.5, pp.442-446, 2005.
DOI : 10.1046/j.1365-2036.2003.01411.x

A. Mackey, L. Green, L. Liang, P. Dinndorf, and M. Avigan, Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease

P. Rutgeerts, B. Feagan, G. Lichtenstein, L. Mayer, S. Schreiber et al., Comparison of scheduled and episodic treatment strategies of infliximab in Crohn???s disease, Gastroenterology, vol.126, issue.2, pp.402-413, 2004.
DOI : 10.1053/j.gastro.2003.11.014

J. Hyams, W. Crandall, S. Kugathasan, A. Griffiths, A. Olson et al., Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn???s Disease in Children, Gastroenterology, vol.132, issue.3, pp.863-873, 2007.
DOI : 10.1053/j.gastro.2006.12.003

F. Ruemmele, A. Lachaux, J. Cezard, A. Morali, C. Maurage et al., Efficacy of Infliximab in Pediatric Crohn??s Disease: A Randomized Multicenter Open-Label Trial Comparing Scheduled to On Demand Maintenance Therapy, Inflammatory Bowel Diseases, vol.134, issue.3, pp.388-394, 2009.
DOI : 10.1053/j.gastro.2008.03.004

L. Batres, P. Mamula, and R. Baldassano, Resolution of Severe Peristomal Pyoderma Gangrenosum With Infliximab in a Child With Crohn Disease, Journal of Pediatric Gastroenterology and Nutrition, vol.34, issue.5, pp.558-560, 2002.
DOI : 10.1097/00005176-200205000-00016

S. Kugathasan, A. Miranda, J. Nocton, B. Drolet, C. Raasch et al., Dermatologic Manifestations of Crohn Disease in Children: Response to Infliximab, Journal of Pediatric Gastroenterology and Nutrition, vol.37, issue.2, pp.150-154, 2003.
DOI : 10.1097/00005176-200308000-00013

R. Rajaraman, Y. Kimura, S. Li, K. Haines, and D. Chu, Retrospective Case Review of Pediatric Patients with Uveitis Treated with Infliximab, Ophthalmology, vol.113, issue.2, pp.308-314, 2006.
DOI : 10.1016/j.ophtha.2005.09.037

E. Maser, R. Villela, M. Silverberg, and G. Greenberg, Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn???s Disease, Clinical Gastroenterology and Hepatology, vol.4, issue.10, pp.1248-1254, 2006.
DOI : 10.1016/j.cgh.2006.06.025

A. Yamada, K. Sono, N. Hosoe, N. Takada, and Y. Suzuki, Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF, Inflamm Bowel Dis, issue.11, pp.161898-1904, 2010.

C. Seow, A. Newman, S. Irwin, A. Steinhart, M. Silverberg et al., Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria, Gut J Pediatr Gastroenterol Nutr, vol.59, issue.741, pp.49-54, 2005.

E. Delong, D. Delong, and D. Clarke-pearson, Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach, Biometrics, vol.44, issue.3, pp.837-845, 1988.
DOI : 10.2307/2531595

C. Cuffari, M. Dubinsky, A. Darbari, L. Sena, and R. Baldassano, Crohn??s Jejunoileitis: The Pediatrician??s Perspective on Diagnosis and Management, Inflammatory Bowel Diseases, vol.39, issue.7, pp.696-704, 2005.
DOI : 10.1007/BF02055108

T. Sipponen, E. Savilahti, P. Karkkainen, K. Kolho, H. Nuutinen et al., Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease, Inflamm Bowel Dis, issue.10, pp.141392-1398, 2008.

M. Jurgens, M. John, J. Cleynen, I. Schnitzler, F. Fidder et al., Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease, Clinical Gastroenterology and Hepatology, vol.9, issue.5, pp.421-427
DOI : 10.1016/j.cgh.2011.02.008

K. Reich, F. Nestle, K. Papp, J. Ortonne, R. Evans et al., Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial, The Lancet, vol.366, issue.9494, pp.3661367-1374, 2005.
DOI : 10.1016/S0140-6736(05)67566-6

E. Maser, R. Villela, M. Silverberg, and G. Greenberg, Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn???s Disease, Clinical Gastroenterology and Hepatology, vol.4, issue.10, pp.1248-1254, 2006.
DOI : 10.1016/j.cgh.2006.06.025

S. Clair, E. Wagner, C. Fasanmade, A. Wang, B. Schaible et al., The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebocontrolled trial, Arthritis Rheum, issue.6, pp.461451-1459, 2002.

T. Hibi, A. Sakuraba, M. Watanabe, S. Motoya, H. Ito et al., Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease, Inflamm Bowel Dis, vol.2012, issue.8, pp.181480-1487

S. Candon, A. Mosca, F. Ruemmele, O. Goulet, L. Chatenoud et al., Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease, Clinical Immunology, vol.118, issue.1, pp.11-19, 2006.
DOI : 10.1016/j.clim.2005.07.010

J. Colombel, W. Sandborn, W. Reinisch, G. Mantzaris, A. Kornbluth et al., Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease, New England Journal of Medicine, vol.362, issue.15, pp.1383-1395253, 2007.
DOI : 10.1056/NEJMoa0904492

C. Cuffari, T. Dassopoulos, L. Turnbough, R. Thompson, and T. Bayless, Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease, Clinical Gastroenterology and Hepatology, vol.2, issue.5, pp.410-417, 2004.
DOI : 10.1016/S1542-3565(04)00127-2

W. Afif, E. Loftus, J. Faubion, W. Kane, S. Bruining et al., Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease, The American Journal of Gastroenterology, vol.26, issue.5, pp.1133-1139, 2010.
DOI : 10.1053/j.gastro.2006.11.041

B. Pariente, P. De-chambrun, G. Krzysiek, R. Desroches, M. Louis et al., Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.16, issue.7, pp.181199-1206
DOI : 10.1002/ibd.21259

W. Van-moerkercke, C. Ackaert, and G. Compernolle, High infliximab trough levels are associated with mucosal healing in Crohn's disease. Program and abstracts of Digestive Disease Week (DDW) 2010, 2010.

A. Morali, I. Gastin, F. Thirion, and N. Kapel, P0721 FECAL CALPROTECTIN AS A MARKER OF INTESTINAL INFLAMMATION IN CHILDREN WITH IBD, THROUGH EVOLUTIONARY STAGES AND UNDER TREATMENT., Journal of Pediatric Gastroenterology and Nutrition, vol.39, issue.Supplement 1, p.331, 2004.
DOI : 10.1097/00005176-200406001-00845